Chris Goss
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Chris Goss sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Chris Goss: 6 sponsored US clinical trials, 3 recruiting.
Chris Goss sponsors 6 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cystic Fibrosis Pulmonary Exacerbation, with 1 trials.
Upper-quartile sponsor footprint
Chris Goss sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
NCT07312734
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283
IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study)
NCT04294043
Observational Study Comparing Home to Office Spirometry
NCT05285410
Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
NCT03801993
Standardized Treatment of Pulmonary Exacerbations II
NCT02781610
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
Where Chris Goss enrollment is open (later-stage tilt)
3 recruiting of 6 indexed (50% open); 3 completed (50%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Cystic Fibrosis Pulmonary Exacerbation (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Chris Goss: open-pipeline peers nationwide
Peers matched on 6 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Chris Goss sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
Related
What to do with this Chris Goss page
6 registered trials is a research-attention snapshot, not an endorsement of Chris Goss or any single study.
- 3 of Chris Goss's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cystic Fibrosis Pulmonary Exacerbation is the condition Chris Goss studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cystic Fibrosis Pulmonary Exacerbation trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Chris Goss pipeline card: 6 registered trials from official public datasets.Report a data error.